Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3882894 | 0.98 | DDB1 (0.44) | DDB1CRBNEPHX2HTR1DQDPR | |
| SCHEMBL3879144 | 0.90 | DDB1 (0.43) | DDB1CRBNEPHX2QDPRDAO | |
| SCHEMBL31122203 | 0.87 | DDB1 (0.51) | DDB1CRBNEPHX2QDPRHTR6 | |
| Hydrochloric Acid SCHEMBL31210159 | 0.85 | DDB1 (0.50) | DDB1CRBNEPHX2QDPRHTR6 | |
| SCHEMBL3872150 | 0.80 | DDB1 (0.41) | DDB1CRBNEPHX2 | |
| SCHEMBL23917459 | 0.76 | KDM4C (0.39) | EPHX2HTR1DSLC6A9HSD11B1 | |
| SCHEMBL8262286 | 0.76 | DAO (0.38) | DAORAF1 | |
| SCHEMBL3126396 | 0.73 | ASIC3 (0.55) | DDB1CRBN | |
| SCHEMBL21326118 | 0.73 | PNMT (0.55) | — | |
| SCHEMBL29586791 | 0.73 | PNMT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342197-B1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| EP-2342197-B1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8153679-B2 | Radiolabelled inhibitors of the glycine 1 transporter | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153679-B2 | Radiolabelled inhibitors of the glycine 1 transporter | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153679-B2 | Radiolabelled inhibitors of the glycine 1 transporter | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2342197-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. Hoffmann-La Roche AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010052143-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | DDB1 4325/4885CRBN 4032/4885EPHX2 1186/4885 |
| US-20100111862-A1 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER | SLC1A5, SLC7A1, SLC1A1 | DDB1 1546/4885CRBN 4144/4885EPHX2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.